This provider's $18.8M in total Medicare payments ranks in the 95th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 22091% from 2014 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 11104% in 2023
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $55.82 | $54.70 | 1.02x | $1.12 | $79.9K | 1.5K | 2 |
| 2015 | $26.64 | $26.07 | 1.02x | $0.57 | $133.9K | 5.1K | 6 |
| 2016 | $62.75 | $61.49 | 1.02x | $1.26 | $63.4K | 1.0K | 2 |
| 2017 | $63.40 | $62.13 | 1.02x | $1.27 | $42.7K | 688 | 1 |
| 2018 | $63.40 | $62.13 | 1.02x | $1.27 | $683.43 | 11 | 1 |
| 2019 | $92.27 | $87.81 | 1.05x | $4.46 | $38.0K | 433 | 1 |
| 2020 | $123.99 | $93.48 | 1.33x | $30.51 | $297.2K | 3.2K | 5 |
| 2021 | $108.47 | $57.33 | 1.89x | $51.14 | $232.9K | 4.1K | 5 |
| 2022 | $200.50 | $51.05 | 3.93x | $149.45 | $158.2K | 3.1K | 8 |
| 2023 | $499.92 | $307.78 | 1.62x | $192.14 | $17.7M | 57.6K | 34 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 81419 | Gene analysis panel for evaluation of genes associated with epilepsy | 1.3K | $3.1M | $2.4K | 1.53x |
| 81317 | Gene analysis (postmeiotic segregation increased 2 [s cerevisiae]) full sequence analysis | 2.1K | $1.4M | $662.97 | 1.53x |
| 81307 | Gene analysis (partner and localizer of brca2) full sequence analysis | 2.0K | $1.4M | $662.97 | 1.53x |
| 81298 | Gene analysis (muts homolog 6 [e coli]) full sequence analysis | 2.1K | $1.3M | $629.01 | 1.53x |
| 81249 | Gene analysis (glucose-6-phosphate dehydrogenase) full sequence analysis | 1.8K | $1.1M | $588.00 | 1.53x |
| 81238 | Gene analysis (coagulation factor ix) full sequence analysis | 1.8K | $1.0M | $588.00 | 1.53x |
| 81325 | Gene analysis (peripheral myelin protein 22), full sequence analysis | 1.3K | $969.1K | $754.19 | 1.53x |
| 81223 | Gene analysis (cystic fibrosis transmembrane conductance regular) full gene sequence | 1.8K | $895.9K | $489.02 | 1.53x |
| 81162 | Gene analysis (breast cancer 1 and 2) of full sequence and analysis for duplication or deletion variants | 257 | $459.6K | $1.8K | 1.53x |
| 81201 | Gene analysis (adenomatous polyposis coli), full gene sequence | 519 | $396.7K | $764.40 | 1.53x |
| 81336 | Gene analysis (survival of motor neuron 1, telomeric) of full sequence | 1.3K | $382.4K | $295.32 | 3.06x |
| 81189 | Gene analysis (cystatin b) of full sequence | 1.3K | $349.9K | $269.33 | 3.02x |
| 81279 | Gene analysis (janus kinase 2) targeted sequence analysis | 1.9K | $346.8K | $181.50 | 1.53x |
| 81339 | Gene analysis (mpl proto-oncogene, thrombopoietin receptor) sequence analysis of exon 10 | 1.9K | $346.8K | $181.50 | 1.53x |
| 81309 | Gene analysis (partner and localizer of brca2) targeted sequence analysis | 1.3K | $344.7K | $269.33 | 1.53x |
| 81286 | Gene analysis (frataxin) of full sequence | 1.3K | $337.7K | $269.33 | 1.53x |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3.4K | $279.3K | $81.49 | 3.31x |
| 81191 | Gene analysis (neurotrophic receptor tyrosine kinase 1) translocation analysis | 1.3K | $264.1K | $203.16 | 1.53x |
| 81192 | Gene analysis (neurotrophic receptor tyrosine kinase 2) translocation analysis | 1.3K | $264.1K | $203.16 | 1.53x |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 1.7K | $195.3K | $113.47 | 1.01x |
This provider submits charges 1.63 times higher than what Medicare actually pays.
A markup ratio of 1.63x means for every $100 Medicare pays, this provider initially charges $163. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in NJ for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Laboratory Corporation Of America Holdings | Raritan, NJ | $1.2B | ⚠️ Flagged |
| Quest Diagnostics Incorporated | Clifton, NJ | $927.2M | ⚠️ Flagged |
| Bioreference Health, Llc | Elmwood Park, NJ | $841.0M | ⚠️ Flagged |
| Accu Reference Medical Lab, Llc | Linden, NJ | $204.9M | ⚠️ Flagged |
| Aculabs Inc | East Brunswick, NJ | $91.5M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data